OBJECTIVE: To characterize and compare the molecular subtypes and profiles of prospectively-accrued newly-diagnosed early- and advanced-stage endometrial cancers (ECs). METHODS: EC patients consented to an IRB-approved protocol of massively parallel sequencing of 410-468 cancer-related genes; 175 ECs of 7 histologic types (n = 135 FIGO stages I/II, n = 40 FIGO stages III/IV) were included. Previously reported sequencing data from 99 additional advanced-stage ECs were retrieved for comparisons. RESULTS: Irrespective of histologic type, all 175 ECs could be stratified into the molecular subtypes, with 75 (43%) being of p53 wild-type, 49 (28%) MMR-deficient, 39 (22%) p53 abnormal and 12 (7%) of POLE molecular subtypes. Subtype distribution, mutational and copy number profiles varied according to histologic type. In endometrioid ECs, genetic alterations varied according to histologic grade. Potential therapeutic targets, including high tumor mutational burden, ERBB2 amplification and PIK3CA hotspot mutations, were found across histologic types in 63% (n = 110) of all ECs. Compared to their early-stage counterparts, advanced-stage endometrioid ECs had a significantly higher fraction of genome altered (median 0.1% vs 12%, p < 0.001) and ARID1B mutations (0% vs 11%, p = 0.01), and advanced-stage serous ECs harbored more frequent ERBB2 amplification (18% vs 8%, p > 0.05) and PIK3CA mutations (46% vs 27%, p > 0.05). Whole-genome doubling was found in advanced- but not early-stage carcinosarcomas and clear cell carcinomas. CONCLUSIONS: Our findings demonstrate the molecular heterogeneity within and across histologic types of EC and the increased genomic complexity of advanced-stage ECs. Molecular subtypes are present across EC histologic types and may help stratify EC patients for prognostic and therapeutic purposes.
OBJECTIVE: To characterize and compare the molecular subtypes and profiles of prospectively-accrued newly-diagnosed early- and advanced-stage endometrial cancers (ECs). METHODS: EC patients consented to an IRB-approved protocol of massively parallel sequencing of 410-468 cancer-related genes; 175 ECs of 7 histologic types (n = 135 FIGO stages I/II, n = 40 FIGO stages III/IV) were included. Previously reported sequencing data from 99 additional advanced-stage ECs were retrieved for comparisons. RESULTS: Irrespective of histologic type, all 175 ECs could be stratified into the molecular subtypes, with 75 (43%) being of p53 wild-type, 49 (28%) MMR-deficient, 39 (22%) p53 abnormal and 12 (7%) of POLE molecular subtypes. Subtype distribution, mutational and copy number profiles varied according to histologic type. In endometrioid ECs, genetic alterations varied according to histologic grade. Potential therapeutic targets, including high tumor mutational burden, ERBB2 amplification and PIK3CA hotspot mutations, were found across histologic types in 63% (n = 110) of all ECs. Compared to their early-stage counterparts, advanced-stage endometrioid ECs had a significantly higher fraction of genome altered (median 0.1% vs 12%, p < 0.001) and ARID1B mutations (0% vs 11%, p = 0.01), and advanced-stage serous ECs harbored more frequent ERBB2 amplification (18% vs 8%, p > 0.05) and PIK3CA mutations (46% vs 27%, p > 0.05). Whole-genome doubling was found in advanced- but not early-stage carcinosarcomas and clear cell carcinomas. CONCLUSIONS: Our findings demonstrate the molecular heterogeneity within and across histologic types of EC and the increased genomic complexity of advanced-stage ECs. Molecular subtypes are present across EC histologic types and may help stratify EC patients for prognostic and therapeutic purposes.
Authors: Karuna Garg; Mario M Leitao; Christine A Wynveen; Gabriel L Sica; Jinru Shia; Weiji Shi; Robert A Soslow Journal: Mod Pathol Date: 2009-10-23 Impact factor: 7.842
Authors: Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz Journal: JCO Precis Oncol Date: 2017-05-16
Authors: Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko K Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim S ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: Siân Jones; Nicolas Stransky; Christine L McCord; Ethan Cerami; James Lagowski; Devon Kelly; Samuel V Angiuoli; Mark Sausen; Lisa Kann; Manish Shukla; Rosemary Makar; Laura D Wood; Luis A Diaz; Christoph Lengauer; Victor E Velculescu Journal: Nat Commun Date: 2014-09-19 Impact factor: 14.919
Authors: Naveena Singh; Lynn Hirschowitz; Richard Zaino; Isabel Alvarado-Cabrero; Maire A Duggan; Rouba Ali-Fehmi; Elizabeth Euscher; Jonathan L Hecht; Lars-Christian Horn; Olga Ioffe; Xavier Matias-Guiu; W Glenn McCluggage; Yoshiki Mikami; Jaume Ordi; Vinita Parkash; M Ruhul Quddus; Charles M Quick; Annette Staebler; Charles Zaloudek; Marisa Nucci; Anais Malpica; Esther Oliva Journal: Int J Gynecol Pathol Date: 2019-01 Impact factor: 2.762
Authors: Saioa López; Emilia L Lim; Stuart Horswell; Kerstin Haase; Ariana Huebner; Michelle Dietzen; Thanos P Mourikis; Thomas B K Watkins; Andrew Rowan; Sally M Dewhurst; Nicolai J Birkbak; Gareth A Wilson; Peter Van Loo; Mariam Jamal-Hanjani; Charles Swanton; Nicholas McGranahan Journal: Nat Genet Date: 2020-03-05 Impact factor: 38.330
Authors: Niamh Conlon; Arnaud Da Cruz Paula; Charles W Ashley; Sheila Segura; Louise De Brot; Edaise M da Silva; Robert A Soslow; Britta Weigelt; Deborah F DeLair Journal: Am J Surg Pathol Date: 2020-05 Impact factor: 6.298